Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter

GlaxoSmithKline's proposed Rx-to-OTC switch of the weight-loss drug Alli (orlistat 60 mg) is "approvable," according to a letter from FDA received by the firm April 6

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet